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Insulin resistance is a major pathological condition associated with obesity and 
metabolic syndrome. Insulin resistance and the renin-angiotensin system are intimately 
linked. We evaluated the role of the renin-angiotensin system in the pathogenesis of 
insulin resistance-associated, non-alcoholic steatohepatitis by using the angiotensin II 
type 1 receptor blocker olmesartan medoxomil in a diabetic rat model. The effects of 
olmesartan on methionine- and choline-deficient (MCD) diet-induced steatohepatitis 
were investigated in obese, diabetic Otsuka Long-Evans Tokushima Fatty (OLETF) rats 
and control Long-Evans Tokushima Otsuka (LETO) rats. Components of the 
renin-angiotensin system were up-regulated in the livers of OLETF rats, compared with 
LETO rats. In OLETF, but not LETO, rats, oral administration of olmesartan for 8 weeks 
ameliorated insulin resistance. Moreover, olmesartan suppressed MCD diet-induced 
hepatic steatosis and the hepatic expression of lipogenic genes (sterol regulatory 
element-binding protein-1c and fatty acid synthase) in OLETF, but not LETO, rats. In 
both OLETF and LETO rats, olmesartan inhibited hepatic oxidative stress 
(4-hydroxy-2-nonenal-modified protein) and expression of NADPH oxidase. Olmesartan 
also inhibited hepatic fibrosis, stellate cell activation, and expression of fibrogenic genes 
(transforming growth factor-β, α1 [I] procollagen, plasminogen activator inhibitor-1) in 
both OLETF and LETO rats. In conclusion, pharmacological blockade of the angiotensin 
II type 1 receptor slows the development of steatohepatitis in the OLETF rat model. This 
angiotensin II type 1 receptor blocker may exert insulin resistance-associated effects 
against hepatic steatosis and inflammation as well as direct effects against the generation 
of reactive oxygen species and fibrogenesis. 
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1. Introduction 
   Non-alcoholic steatohepatitis is a common liver disease and a leading cause of 
cryptogenic cirrhosis (Angulo, 2002; Brunt, 2001; Caldwell et al., 1999; Farrell and 
Larter, 2006; Reid, 2001). Non-alcoholic steatohepatitis is also strongly associated with 
obesity, type 2 diabetes, hypertension, and metabolic syndrome (DeFronzo and 
Ferrannini, 1991; Marceau et al., 1999; Reaven, 1988).  
   We recently reported a rat model of non-alcoholic steatohepatitis that exhibits insulin 
resistance, abundant visceral fat tissue, postprandial hyperglycemia, and hypertension. 
We have used this model to demonstrate that insulin resistance is an important therapeutic 
target in ameliorating steatohepatitis (Ota et al., 2007).  
   The renin-angiotensin system is intimately associated with obesity and metabolic 
syndrome. Much evidence suggests an interaction between the renin-angiotensin system 
and insulin action (Prasad and Quyyumi, 2004). Angiotensin II is a pro-oxidant cytokine, 
and angiotensin II-induced NADPH oxidase activation impairs insulin signaling in 
skeletal muscle cells (Wei et al., 2006). Angiotensin II type 1 receptor blockers have been 
shown to ameliorate insulin resistance in rodents (Okada et al., 2004).  
   The interaction between angiotensin II and the angiotensin II type 1 receptor also plays 
a pivotal role in liver fibrosis development, through a phenotypic transition of quiescent 
hepatic stellate cells into myofibroblastic hepatic stellate cells (Bataller et al., 2003a). 
Furthermore, all renin-angiotensin system components are up-regulated in hepatic 
stellate cells isolated from human cirrhotic livers and in culture-activated stellate cells 
that generate angiotensin II (Bataller et al., 2003b). These findings implicate the 
renin-angiotensin system in the activation of stellate cells and liver fibrogenesis, which 
are involved in the development of insulin resistance-associated steatohepatitis (Ota et al., 
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2007).  
   Recently, Hirose et al. reported that an angiotensin II type 1 receptor blocker inhibited 
hepatic fibrosis in Wistar rats fed a methionine- and choline-deficient (MCD) diet (Hirose 
et al., 2007). However, the steatohepatitis model used in that study did not exhibit insulin 
resistance (Rinella and Green, 2004), although insulin resistance is typically involved in 
the development of steatohepatitis in humans. Thus, the precise mechanism underlying 
the association between the improvement in steatohepatitis and the pharmacological 
blockade of angiotensin II type 1 receptor remains to be determined.  
   To address these issues, we investigated the effects of an angiotensin II type 1 receptor 
blocker, olmesartan, not only in a model of non-alcoholic steatohepatitis without insulin 
resistance but also in a model with insulin resistance that we recently established (Ota et 
al., 2007). By comparing these models, we examined the role of the renin-angiotensin 
system in the development of non-alcoholic steatohepatitis and the complex mechanism 
underlying improvement after angiotensin II type 1 receptor blockade.  
 
2. Materials and methods 
 
2.1. Animals and experimental design  
   We used male Otsuka Long-Evans Tokushima Fatty (OLETF) rats (Otsuka 
Pharmaceutical, Tokushima, Japan) as an established animal model of obese type 2 
diabetes (Kawano et al., 1992) and male Long-Evans Tokushima Otsuka (LETO) rats 
(Otsuka Pharmaceutical) as control animals. LETO rats originated from the same colony 
as the OLETF rats; however, as a result of selective breeding, they do not develop 
diabetes. Four-week-old OLETF and LETO rats were housed under controlled 
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temperature (25°C), humidity, and lighting (12-h artificial light/dark cycle). The animals 
were given free access to standard laboratory rat chow and tap water.  
   At 24 weeks of age, OLETF rats were divided into two experimental groups and fed for 
8 weeks as follows: (1) MCD diet (Oriental Yeast Co., Tokyo, Japan; n = 8) and (2) MCD 
diet mixed with 0.01% olmesartan medoxomil (donated by Daiichi Sankyo Company, 
Ltd., Tokyo, Japan), delivering a dose of 5 mg/kg per day (n = 5). Two groups of 
non-diabetic LETO rats were kept on the same regimen: (3) MCD diet (n = 8) and (4) 
MCD + olmesartan diet (n = 5).  
   During absorption in the gastrointestinal tract, orally administered olmesartan 
medoxomil is converted to olmesartan, the pharmacologically active metabolite. The 
medoxomil moiety is released as a diacetyl, which is rapidly cleared by further 
metabolism and excretion (Laeis et al., 2001).  
   The body weight and food intake of the individuals in each group were recorded weekly. 
Systolic and diastolic blood pressures were measured using tail-cuff plethysmography 
(BP-98A, Softron, Tokyo, Japan) in conscious pre-warmed rats, both before the start of 
olmesartan treatment and 8 weeks after.  
   All animal procedures were performed in accordance with the standards set forth in the 
Guidelines for the Care and Use of Laboratory Animals at the Takara-machi campus of 
Kanazawa University. 
 
2.2 Blood sampling and analysis 
   Blood samples were obtained from the tail vein of rats at 24 and 32 weeks of age, after 
a 12-h fast and under diethyl ether anesthesia. Blood glucose was determined by the 
glucose-oxidase method using Glucocard (Aventis Pharma, Tokyo, Japan). After 
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centrifugation, the serum was frozen at -80°C for subsequent measurement of alanine 
aminotransferase (ALT), 8-isoprostane, triglycerides, free fatty acid, total cholesterol, 
high-density lipoprotein cholesterol (HDL-cholesterol), and tumor necrosis factor-α 
(TNF-α) levels. Serum ALT was determined using a spectrophotometric assay kit (Sigma, 
St. Louis, MO) according to the manufacturer’s instructions. Circulating 8-isoprostane 
(Cayman Chemical, Ann Arbor, MI) and TNF-α (Biosource International, Camarillo, 
CA) were determined using ELISA kits according to the manufacturers’ instructions. 
Serum free fatty acid levels were determined using the non-esterified fatty acid (NEFA) 
C-test (Wako, Osaka, Japan). Total cholesterol and HDL-cholesterol concentrations were 
quantified using a colorimetric assay as described previously (Ota et al., 2003). 
 
2.3 Evaluation of insulin sensitivity 
   After 8 weeks, the rats underwent an oral glucose tolerance test following a 12-h fast. 
Glucose (2 g/kg) was administered orally. Blood was drawn from the tail vein at 0, 30, 60, 
and 120 min for measurements of blood glucose concentration. An insulin tolerance test 
was performed following a 4-h fast. Rats were given an intraperitoneal injection of 
insulin (0.5 U/kg), and blood was drawn from the tail vein at 0, 15, 30, 45, and 60 min for 
measurements of blood glucose concentration. The area under the curve for the 
percentage basal glucose during the insulin tolerance test was estimated using the linear 
trapezoidal method. 
 
2.4. Measurement of serum/liver triglycerides 
   After 8 weeks, the rats were sacrificed and the liver weight, epididymal fat weight, 
mesenteric fat weight, and liver triglyceride content were measured. To quantify hepatic 
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triglycerides, livers were lysed in a buffer from a commercially available kit (TG E-test; 
Wako), and the lysate was sonicated. The triglyceride content of the homogenate and 
serum was determined using the same kit, according to the manufacturer's instructions. 
 
2.5. Morphological analysis and immunohistochemistry 
   Rat livers were fixed in 10% buffered formalin and embedded in paraffin. After staining 
with hematoxylin-eosin and Azan, the severity of hepatic histopathology was scored by a 
single pathologist, who was blind to the experimental design. Steatosis grade 
(inflammation) and stage (fibrosis) were semi-quantitatively evaluated according to the 
standard criteria for grading and staging non-alcoholic steatohepatitis, with minor 
modifications (Brunt et al., 1999). The degree of steatosis was scored based on the 
percentage of hepatocytes containing lipid droplets. Inflammation was scored as follow: 
0, no hepatocyte injury or inflammation; 1, mild focal injury; 2, noticeable injury; and 3, 
severe zone 3 hepatocyte injury or inflammation. Fibrosis was scored as follows: 0, no 
fibrosis; 1, pericellular and perivenular fibrosis; 2, focal bridging fibrosis; 3, extensive 
bridging fibrosis with lobular distortion; and 4, cirrhosis.  
   Slides were immunostained with monoclonal mouse anti-human α-smooth muscle actin 
(DAKO, Kyoto, Japan) or anti-rabbit transforming growth factor-β (TGF-β; Santa Cruz 
Biotechnology, Santa Cruz, CA). The reactions were visualized by the 
immunoperoxidase technique using an Envision kit (DAKO). Peroxidase activity was 
identified by reaction with 3',3'-diaminobenzidine (DAB, Sigma). Two blinded observers 
independently evaluated each section. Cells with positive staining for anti-α-smooth 
muscle actin or anti-TGF-β were expressed as a percentage of the field, using WinROOF 
software (version 5.7, Mitani Shoji Co., Ltd., Fukui, Japan). 
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 2.6. Western blot analysis 
   Livers were homogenized in lysis buffer containing 20 mM Tris-HCl (pH 7.5), 5 mM 
EDTA, 1% NP-40, and a protease inhibitor cocktail (Pierce Biotechnology, Rockford, IL). 
Homogenized proteins (15 μg/lane) were separated by electrophoresis in 4-20% gradient 
SDS- polyacrylamide gels (Daiichi Pure Chemicals, Tokyo, Japan) at 130 V over 2 h. The 
separated proteins were transferred to polyvinylidene difluoride membranes (Millipore, 
Billerica, MA) using a Transblot apparatus (Bio-Rad Laboratories, Hercules, CA). The 
membranes were blocked in a buffer containing 5% nonfat milk, 50 mM Tris (pH 7.6), 
150 mM NaCl, and 0.1% Tween 20 (TBS-T) for 1 h. They were then incubated for 1 h 
with a monoclonal anti-4-hydroxy-2-nonenal (4-HNE) antibody (NOF, Tokyo, Japan) 
diluted 1:200 in 5% bovine serum albumin (BSA) in TBS-T. Then the membranes were 
washed in TBS-T and incubated with a horseradish peroxidase-conjugated secondary 
antibody (Cell Signaling Technology, Beverly, MA) at 1:2000 dilution in 5% BSA in 
TBS-T for 1 h. The 4-HNE-modified proteins were visualized using a luminescent image 
analyzer LAS-3000 (FUJIFILM, Tokyo, Japan). 
 
2.7. Real-time quantitative polymerase chain reaction (PCR) 
   Total RNA was extracted from each liver using an RNeasy mini kit (Qiagen, Valencia, 
CA) as described previously (Takamura et al., 2004). Real-time quantitative PCR was 
performed for the angiotensin II types 1 and 2 receptors, angiotensinogen, sterol 
regulatory element-binding protein (SREBP)-1c, fatty acid synthase (FAS), acyl-CoA 
oxidase 1 (Acox 1), cytochrome P450 2e1 (CYP2E1), NADPH oxidase 1 (Nox 1), 
NADPH oxidase 4 (Nox 4), neutrophil cytosolic factor 1 (Ncf 1, also known as p47phox, 
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Noxo 2), glutathione peroxidase 1 (Gpx 1), TGF-β, plasminogen activator inhibitor-1 
(PAI-1), and α1(I) procollagen (collagen I) mRNAs, using the ABI Prism 7900HT 
sequence detection system (Applied Biosystems, Foster City, CA).  
   Primers and TaqMan probes for angiotensin II type 1 receptor, angiotensin II type 2 
receptor, angiotensinogen, FAS, Acox 1, CYP2E1, Nox 1, Nox 4, Ncf 1, Gpx 1, PAI-1, 
and collagen I were from Applied Biosystems. Primers and TaqMan probes for 
SREBP-1c and TGF-β were designed using Primer Express software (version 1.5, 
Applied Biosystems). The primers used were 5′-GGGCAGCTCTGTACTCCTTCAA-3′ 
(forward) and 5′-GCTAAGCTGTCCCGCAGGTA-3′ (reverse) for SREBP-1c, and 
5′-TTCCTGGCGTTACCTTGGT-3′ (forward) and 5′-GCCACTGCCGGACAACT-3′ 
(reverse) for TGF-β. The TaqMan probes used were 
5′-AGCCAGCCTGGCCATCTGTGAGA-3′ for SREBP-1c and 
5′-TACGCCTGAGTGGCTGTCTTTTGA-3′ for TGF-β. To control for variation in the 
amount of DNA available for PCR in the different samples, gene expression of the target 
sequence was normalized relative to an endogenous control, 18S ribosomal RNA (18S 
rRNA TaqMan control reagent kit; Applied Biosystems). The PCR conditions were one 
cycle at 50°C for 2 min and 95°C for 10 min, followed by 50 cycles of 95°C for 15 s and 
58°C for 1 min. 
 
2.8. Statistical analysis 
   All results are expressed as means ± S.E.M. Means were compared by one-way analysis 
of variance (ANOVA). The Bonferroni multiple comparisons procedure was used to 
determine differences between pairs. Between-group differences for continuous variables 
were assessed using univariate analysis with Student’s t-tests. Values of P <0.05 were 
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deemed statistically significant. All calculations were performed using SPSS software 
(version 11.0 for Windows, SPSS Inc., Chicago, IL). 
 
3. Results 
3.1. Metabolic parameters and insulin sensitivity  
   As previously described (Ota et al., 2007), OLETF rats at 24 weeks of age showed 
obesity, especially visceral fat obesity, hyperglycemia, hyperinsulinemia, and 
hypertension, compared with LETO rats (data not shown). The expression of 
angiotensinogen and angiotensin II type 1 receptor mRNA in the livers of OLETF rats 
was up-regulated compared with that in LETO rats (Fig. 1). In contrast, angiotensin II 
type 2 receptor gene expression was not observed in the liver (data not shown). The 
angiotensin II type 2 receptor is expressed at high levels in the developing fetus 
(Matsubara, 1998). In the adult, its expression is restricted to the adrenals, uterus, ovary, 
heart, and specialized nuclei in the brain (Cox et al., 1993; Matsubara, 1998; Shanmugam 
et al., 1995). We recently reported that hepatic expression of the angiotensin II type 2 
receptor was not detectable by real-time PCR analysis in fatty liver disease in mice and 
humans (Takeshita et al., 2008).  
   The metabolic parameters of rats fed the MCD diet for 8 weeks are shown in Table 1. 
The MCD diet caused weight loss but did not affect the physical appearance or behavior 
of the rats, as described previously (George et al., 2003). The MCD diet decreased serum 
lipid levels in OLETF rats (data not shown). It has been reported that the MCD diet 
decreases serum lipid levels in obese diabetic mice, probably as a results of increased 
uptake of fatty acid and reduced secretion of very low-density lipoprotein by the liver 
(Rinella et al., 2008).  
 11 
   Olmesartan administration did not affect the health of the rats; food intake and body 
weight remained the same. However, olmesartan significantly decreased the systolic and 
diastolic blood pressure and liver weight in both OLETF and LETO rats, although 
circulating fasting glucose and lipid levels were not affected (Table 1). Additionally, 
olmesartan significantly decreased fasting serum insulin levels in OLETF, but not in 
LETO, rats. 
   We have previously described insulin resistance as an important factor in the pathology 
and development of steatohepatitis (Ota et al., 2007). Here, we conducted oral glucose 
tolerance and insulin tolerance tests at 8 weeks to evaluate the effect of olmesartan on 
insulin sensitivity (Fig. 2). After 60 min of glucose administration, blood glucose levels 
were significantly reduced in olmesartan-treated OLETF rats, whereas blood glucose 
levels were unaffected by this treatment throughout the test period in LETO rats (Fig. 2A). 
Additionally, as demonstrated by the area under the curve, the hypoglycemic effect of 
insulin was significantly enhanced in OLETF rats treated with olmesartan (P < 0.05); in 
contrast, olmesartan treatment had no effect on this parameter in LETO rats (Fig. 2B). 
Olmesartan ameliorated insulin resistance in OLETF, but not in LETO, rats.  
 
3.2. MCD diet-induced steatohepatitis 
   Photomicrographs of liver sections obtained from OLETF and LETO rats fed the MCD 
or MCD + olmesartan diet for 8 weeks are shown in Figs. 3A and B. Our quantitative 
analysis of the severity of steatosis, inflammation, and fibrosis is shown in Fig. 3C. The 
MCD diet caused marked macrovesicular steatosis, with focal lymphocytic infiltration 
and hepatocellular drop-outs, in LETO rats, whereas it caused intense lobular 
inflammation and perivenular and pericellular fibrosis, prominently in zone 3, in OLETF 
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rat livers (Fig. 3A, B, C). Olmesartan treatment attenuated fibrogenesis in LETO rats on 
the MCD diet. In contrast, in OLETF rat livers, olmesartan treatment significantly 
improved not only fibrogenesis but also steatosis and inflammation induced by the MCD 
diet. 
   Consistent with the histological assessment of steatosis, olmesartan treatment 
significantly decreased the hepatic triglyceride content and serum ALT level in OLETF, 
but not LETO, rats (Fig. 4A, B). 
 
3.3. Effect of olmesartan treatment on lipogenic gene expression 
   To address the molecular basis of olmesartan’s actions in steatosis, we assessed the 
expression levels of key genes involved in fatty acid synthesis, by quantitative real-time 
PCR. Hepatic expression of SREBP-1c, a transcriptional regulator of fatty acid synthesis 
in the liver (Ide et al., 2004; Shimano et al., 1996), and its downstream target gene, FAS, 
were coordinately up-regulated in OLETF rats, compared with LETO rats (Fig. 5A, B). In 
OLETF rats, olmesartan treatment suppressed the hepatic expression of SREBP-1c and 
FAS by 52 and 72%, respectively. However, olmesartan treatment had no effect on these 
parameters in LETO rats. 
 
3.4. Effect of olmesartan treatment on oxidative stress 
   Given that reactive oxygen species may be involved in the development of 
steatohepatitis (Garcia-Ruiz et al., 1995) and angiotensin II type 1 receptor blockers 
suppress hepatic reactive oxygen species generation in experimental models of liver 
fibrosis (Bataller et al., 2005; Bataller et al., 2003c), we investigated the effect of 
olmesartan on 4-HNE-modified hepatic proteins and circulating 8-isoprostane levels, 
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which are markers for cumulative oxidative stress. The levels of hepatic proteins 
modified with 4-HNE, a major aldehyde end-product of membrane lipid peroxidation, 
decreased after olmesartan treatment in both OLETF and LETO rats (Fig. 6A). 
Circulating 8-isoprostane levels also decreased after olmesartan treatment in OLETF rats 
(Fig. 6B). These results suggest that olmesartan treatment suppressed MCD diet-induced 
reactive oxygen species generation. 
   Oxidative stress is determined by the balance between reactive oxygen species 
production and antioxidant enzyme activity (Nordberg and Arner, 2001). We investigated 
several genes thought to be involved in reactive oxygen species generation. Hepatic 
expression of the NADPH oxidase complex component Ncf 1, also known as 
p47phox/Noxo 2, was up-regulated during the course of MCD diet-induced steatohepatitis 
(Fig. 6C). However, expression levels of genes encoding peroxisomal Acox 1 and 
CYP2E1 were unaffected. 
   We next examined the effect of olmesartan treatment on the expression of NADPH 
oxidase complex components, which include membrane-bound cytochrome b558 (Nox 
1-5 and p22phox) and the cytosolic subunit Ncf 1 (De Minicis et al., 2006). We examined 
the expression of Nox 1, which is involved in angiotensin II-mediated hypertension 
(Matsuno et al., 2005); Nox 4, which is important for the activation of mouse hepatic 
stellate cells (De Minicis et al., 2006); and Ncf 1, which plays a key role in the activation 
of NADPH oxidase (Wei et al., 2006) (Fig. 6D, E, F). Olmesartan treatment 
down-regulated hepatic expression of Nox 1, Nox 4, and Ncf 1 in OLETF rats; the 
expression of Nox 1 and Ncf 1 was also down-regulated in LETO rats. In contrast, 
olmesartan treatment up-regulated the expression of Gpx 1, an antioxidant enzyme, in 
OLETF rats (Fig. 6G). 
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 3.5. Effect of olmesartan treatment on the circulating TNF-α level 
   TNF-α, an inflammatory cytokine produced in adipose tissue and macrophages, 
aggravates steatohepatitis (Crespo et al., 2001) and insulin resistance (Houstis et al., 
2006) through the generation of reactive oxygen species. Serum TNF-α was significantly 
elevated in OLETF rats compared with LETO rats (Fig. 7). Olmesartan treatment 
significantly (P < 0.05) decreased the serum TNF-α level in OLETF rats, while the 
TNF-α level was unchanged in LETO rats. Thus, olmesartan may improve steatohepatitis 
and insulin resistance, in part, by reducing the TNF-α level in OLETF rats. 
 
3.6.Effect of olmesartan treatment on hepatic fibrosis  
   Angiotensin II stimuli such as oxidative stress and inflammatory cytokines also activate 
hepatic stellate cells, which are major sources of collagen and other extracellular matrix 
proteins, in liver fibrosis (Friedman, 2000; Leonarduzzi et al., 1997). We performed an 
immunohistochemical analysis of α-smooth muscle actin, an activated hepatic stellate 
cell marker, at 8 weeks. Representative photomicrographs of liver sections stained with 
an anti-α-smooth muscle actin antibody are shown in Fig. 8A. We morphometrically 
quantified the area of the liver section that was positive for α-smooth muscle actin in the 
four groups. The number of activated stellate cells increased to a greater degree in 
OLETF rats than in LETO rats. Development of α-smooth muscle actin-positive cells was 
completely suppressed by olmesartan treatment in both OLETF and LETO rats receiving 
the MCD diet.  
   In parallel with the activation of hepatic stellate cells, hepatic expression of TGF-β, a 
key inducer of fibrogenesis, increased to a greater degree in OLETF rats than in LETO 
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rats (Fig. 8B). Olmesartan treatment completely suppressed hepatic TGF-β expression in 
both groups. These results are consistent with the histological observation that the MCD 
diet induced more severe fibrosis in OLETF rats than in LETO rats and that olmesartan 
ameliorated liver fibrosis in both rat types.  
   To assess the mechanism underlying olmesartan-mediated attenuation of hepatic 
fibrosis, we examined the hepatic gene expression of TGF-β and its target genes, collagen 
I and PAI-1 (Fig. 8C, D, E). In OLETF rats, olmesartan treatment inhibited the 
up-regulation of hepatic TGF-β, collagen I, and PAI-1 by 62, 68, and 61%, respectively. 
Olmesartan also inhibited the up-regulation of TGF-β, collagen I, and PAI-1 in LETO rats, 
by 72, 55, and 70%, respectively. 
 
4. Discussion 
   In the present study, genes for renin-angiotensin system components such as 
angiotensinogen and the angiotensin II type 1 receptor were up-regulated in the livers of 
OLETF rats compared with LETO rats, suggesting that the renin-angiotensin system is 
locally activated in the liver of rats with obesity-related diabetes. Activation of the 
renin-angiotensin system has been implicated in insulin resistance, partly via an 
interaction with insulin signaling (Shiuchi et al., 2004; Velloso et al., 1996). We have 
recently shown that insulin resistance accelerated the pathogenesis of experimental 
steatohepatitis in OLETF, but not in LETO, rats (Ota et al., 2007). Here, we investigated 
the effects of the angiotensin II type 1 receptor blocker olmesartan in OLETF and LETO 
rats. An inhibitory effect of olmesartan on the development of steatosis and inflammation 
was observed in OLETF rats, but not in LETO rats, suggesting that olmesartan prevented 
the development of steatohepatitis by its effects on insulin resistance in the liver of the 
 16 
obese, diabetic rats. The olmesartan-induced reduction of serum TNF-α may also 
contribute to the improvement in insulin resistance (Houstis et al., 2006). 
   It has been suggested that angiotensin II type 1 receptor blockers that have with PPARγ 
activity, such as telmisartan, beneficially affect insulin sensitivity (Schupp et al., 2004). 
However, that is not the case with olmesartan. The use of ramipril, an 
angiotensin-converting enzyme inhibitor, has recently been reported to increase 
regression to normoglycemia in persons with impaired fasting glucose levels or impaired 
glucose tolerance (Bosch et al., 2006). Togashi et al. (Houstis et al., 2006; Togashi et al., 
2000) showed that another angiotensin-converting enzyme inhibitor, temocapril, and 
olmesartan produced a reduction in the TNF-α level that correlated with insulin resistance 
in rat skeletal muscle. They also demonstrated that angiotensin II increased TNF-α 
secretion from cultured muscle tissue. These findings suggest that blockade of the 
renin-angiotensin system may be an attractive target in the treatment of insulin resistance. 
   SREBP-1c is a master gene in the regulation of hepatic lipogenesis, via the control of 
lipogenic genes such as FAS (Shimano et al., 1996). It also plays a central role in the 
development of high-fat diet-induced insulin resistance in the liver, by down-regulation 
of insulin receptor substrate 2 (Ide et al., 2004). Our results demonstrated that the genes 
for lipogenic SREBP-1c and FAS were up-regulated in concert with the hepatic 
triglyceride content in OLETF rats. This suggests that SREBP-1c-mediated de novo 
synthesis of fatty acids is increased in the insulin-resistant state and plays a significant 
role in the development of hepatic steatosis in this model. The olmesartan-induced 
reduction of hepatic SREBP-1c and FAS mRNA levels may contribute to the 
improvement in hepatic steatosis and possibly insulin resistance (Ide et al., 2004) in 
OLETF rats.  
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   Activated hepatic stellate cells contain a non-phagocyte type of NADPH oxidase that is 
stimulated by pro-inflammatory and fibrogenic mediators such as angiotensin II. In 
contrast, Kupffer cells contain phagocyte-type NADPH oxidase that is activated by 
bacterial products and TNF-α. In chronic liver disease, activation of both types of 
NADPH oxidases leads to increased reactive oxygen species generation, resulting in 
inflammation and fibrogenesis (De Minicis et al., 2006). Our results suggest that local 
activation of the renin-angiotensin system and an increased level of serum of TNF-α 
contribute to the activation of non-phagocytic and phagocytic types of NADPH oxidase, 
respectively. Olmesartan treatment down-regulated hepatic expression of NADPH 
oxidase via the pharmacological blockade of angiotensin II type 1 receptors and 
decreased serum TNF-α. Additionally, olmesartan treatment up-regulated the hepatic 
expression of the antioxidant enzyme Gpx 1 in OLETF rats. These findings are consistent 
with previous results showing that the angiotensin II type 1 receptor blocker irbesartan 
reversed high-glucose-induced impairment of Gpx activity and mRNA expression in 
adolescents with diabetic angiopathy (Chiarelli et al., 2005). These pleiotropic effects of 
olmesartan collectively decreased 4-HNE-modified proteins and attenuated the 
development of hepatic fibrosis in both OLETF and LETO rats. 
   In the liver, circulating or tissue angiotensin II–angiotensin II type 1 receptor 
interactions have been implicated in the pathophysiology of fibrosis. Indeed, it has been 
demonstrated that an increase in systemic angiotensin II, via infusion of angiotensin II 
into bile duct-ligated rats, augmented hepatic fibrosis and promoted inflammation and 
oxidative stress (Bataller et al., 2005). It has also been reported that renin-angiotensin 
system blockers protect against experimental liver fibrosis caused by CCl4 administration 
(Kanno et al., 2003) and bile duct ligation (Kurikawa et al., 2003; Yang et al., 2005). In 
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our study, olmesartan inhibited key pathogenic events induced by the MCD diet, 
including the accumulation of activated stellate cells and fibrogenic TGF-β, PAI-1, and 
collagen I, thereby preventing the development of liver fibrosis in both the presence 
(OLETF) and absence (LETO) of insulin resistance. Thus, in addition to improving 
insulin resistance as described above, angiotensin II type 1 receptor blockers may also be 
involved in the attenuation of hepatic fibrosis. 
   During the preparation of this manuscript, Hirose et al. (Hirose et al., 2007) reported 
that olmesartan inhibited hepatic fibrosis in Wistar rats fed an MCD diet. However, they 
used a model of steatohepatitis without insulin resistance (Rinella and Green, 2004). In 
the present study, we used not only a model of non-alcoholic steatohepatitis without 
insulin resistance but also a model with insulin resistance, which we recently established 
(Ota et al., 2007). This is important because insulin resistance is usually involved in the 
development of non-alcoholic steatohepatitis in humans. By comparing these models, we 
showed for the first time that the pharmacological blockade of angiotensin II type 1 
receptor ameliorated the pathology of steatohepatitis, by improving insulin 
resistance-associated lipid metabolism and inflammation and by direct inhibition of 
reactive oxygen species generation and fibrogenesis. 
   A pilot study has shown that the angiotensin II type 1 receptor blocker losartan reduced 
the severity of hepatic histological defects in patients with non-alcoholic steatohepatitis 
(Yokohama et al., 2004). Thus, olmesartan may also be an effective clinical treatment for 
non-alcoholic steatohepatitis, particularly in patients with the complication of insulin 
resistance. Prospective randomized clinical trials are needed to investigate the beneficial 
effects of renin-angiotensin system inhibitors in obese and/or diabetic patients with 
non-alcoholic steatohepatitis. 
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Fig. 1. Activation of the renin-angiotensin system in the liver of the insulin-resistant 
Otsuka Long-Evans Tokushima Fatty (OLETF) rat. Hepatic expression of (A) 
angiotensinogen and (B) angiotensin II type 1 receptor was up-regulated in OLETF rats, 
compared with that in Long-Evans Tokushima Otsuka (LETO) rats. Gene expression was 
assessed at 24 weeks of age using real-time quantitative polymerase chain reaction (PCR). 
The results were normalized against 18S ribosomal RNA (rRNA) mRNA expression. 
Values are the mean ± S.E.M. (n = 8). *P < 0.01. 
 
Fig. 2. Olmesartan decreased post-challenge glucose and insulin sensitivity in OLETF 
rats fed the MCD diet. Blood glucose levels during the (A) oral glucose tolerance test and 
(B) insulin tolerance test in OLETF rats and LETO rats fed the MCD diet or 
MCD+olmesartan diet for 8 weeks. Values are means ± S.E.M. (n = 4). Values are 
expressed relative to the basal blood glucose level (100%) in B. *P < 0.05, versus OLETF 
rats fed the MCD diet; †P < 0.05, versus LETO rats fed the MCD diet. 
 
Fig. 3. Olmesartan treatment slowed the pathological progression of diet-induced 
steatohepatitis. Representative photomicrographs show the effects of the MCD diet 
(white bars, n = 8) and the MCD+olmesartan diet (hatched bars; n = 5) on the liver 
histology in OLETF and LETO rats. Rats were fed the diets for 8 weeks. 
Paraffin-embedded sections were stained with (A) hematoxylin-eosin or (B) Azan. Bar, 
200 μm. Original magnification, ×100. (C) Blind observers scored the hematoxylin-eosin 
stained sections for the severity of steatosis and grade (inflammation); azan-stained 
 24 
samples were scored for stage (fibrosis). The scoring criteria are described in the 
Materials and Methods. Values are means ± S.E.M. *P < 0.05. †P < 0.05 versus LETO rats 
fed the MCD diet. 
 
Fig. 4. Olmesartan improved insulin resistance-accelerated hepatic fat accumulation and 
liver injury in diet-induced non-alcoholic steatohepatitis. LETO and OLETF rats were fed 
the MCD (white bars, n = 8) or MCD+olmesartan diet (hatched bars, n = 5) for 8 weeks. 
(A) Hepatic triglyceride content, and (B) serum alanine aminotransferase (ALT) levels. 
Values are the mean ± S.E.M. *P < 0.05 versus the MCD diet. †P < 0.05 versus LETO rats 
fed the MCD diet. 
 
Fig. 5. Olmesartan suppressed hepatic expression of lipogenic genes in OLETF rats fed 
the MCD diet. LETO rats and OLETF rats were fed the MCD (white bars, n = 8) or 
MCD+olmesartan diet (hatched bars, n = 5) for 8 weeks. Real-time quantitative PCR was 
used to measure hepatic expression of (A) sterol regulatory element-binding protein 
(SREBP)-1c and (B) fatty acid synthase (FAS) in LETO and OLETF rats fed the MCD 
diet. Results were normalized against 18S rRNA. Values are means ± S.E.M. *P < 0.05. 
†P < 0.05 versus LETO rats fed the MCD diet.  
 
Fig. 6. Olmesartan inhibited oxidative stress and hepatic expression of NADPH oxidase. 
LETO and OLETF rats were fed the MCD (white bars, n = 8) or MCD+olmesartan diet 
(hatched bars, n = 5) for 8 weeks. (A) Western blots of 4-hydroxy-2-nonenal-modified 
hepatic proteins in LETO and OLETF rats. Protein loads were normalized to 
15 μg/sample. (B) Serum 8-isoprostane. (C) Time course of hepatic mRNA expression 
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for neutrophil cytosolic factor 1 (Ncf 1, also known as p47phox/Noxo 2), acyl-CoA oxidase 
1 (Acox 1), and cytochrome P450 2e1 (CYP2E1) in OLETF rats fed the MCD diet. 
Real-time quantitative PCR was used to measure the hepatic expression of (D) Ncf 1, (E) 
NADPH oxidase 1 (Nox 1), (F) NADPH oxidase 4 (Nox 4), and (G) glutathione 
peroxidase 1 (Gpx 1). Results were normalized against 18S rRNA. Values are means ± 
S.E.M. *P < 0.05. †P < 0.05, versus LETO rats fed the MCD diet. 
 
Fig. 7. Olmesartan suppressed the circulating tumor necrosis factor-α (TNF-α) level in 
OLETF rats fed the MCD diet. LETO and OLETF rats were fed the MCD (white bars, n = 
8) or MCD+olmesartan diet (hatched bars, n = 5) for 8 weeks. Serum TNF-α levels were 
measured using an ELISA kit according to the manufacturer’s instructions. Values are 
means ± S.E.M. *P < 0.05. †P < 0.05 versus LETO rats. 
 
Fig. 8. Olmesartan inhibited hepatic fibrosis. LETO and OLETF rats were fed the MCD 
(white bars, n = 8) or MCD+olmesartan diet (hatched bars, n = 5) for 8 weeks. Sections 
were immunohistochemically stained with (A) anti-α-smooth muscle actin and (B) 
anti-TGF-β antibody and were counterstained with hematoxylin. Positive staining for 
α-smooth muscle actin or TGF-β is indicated by arrows. Bar, 200 μm. Original 
magnification, ×100. Real-time quantitative PCR was used to measure the hepatic 
expression of (C) transforming growth factor-β (TGF-β), (D) α1(I) procollagen (collagen 
I), and (E) plasminogen activator-1 (PAI-1). Results were normalized against 18S rRNA. 
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Effects of olmesartan medoxomil treatment on metabolic parameters in rats fed a 
methionine- and choline-deficient (MCD) diet for 8 weeks. 
 LETO OLETF 
 olmesartan (–) olmesartan (+) olmesartan (–) olmesartan (+) 
Body weight (g) 382 ± 6 372 ± 9 404 ± 6 385 ± 13 
Liver weight (g) 9.6 ± 0.3 8.4 ± 0.3a 14.0 ± 0.5b 12.6 ± 0.8a
Epididymal fat pad weight (g) 3.0 ± 0.3 2.9 ± 0.4 3.5 ± 0.2b 4.0 ± 0.5 
Mesenteric fat weight (g) 3.1 ± 0.1 3.6 ± 0.4 7.1 ± 0.7b 6.9 ± 0.9 
Systolic blood pressure (mmHg) 109 ± 1 74 ± 3a 139 ± 9b 91 ± 2a
Diastolic blood pressure (mmHg) 94 ± 3 61 ± 2a 114 ± 7b 81 ± 2a
Fasting blood glucose (mmol/L) 5.9 ± 0.5 5.8 ± 0.3 6.5 ± 0.4 6.1 ± 0.4 
Fasting serum insulin (pmol/L) 172 ± 29 240 ± 141 497 ± 125b 170 ± 66a
Serum triglyceride (mmol/L) 1.01 ± 0.08 1.00 ± 0.04 1.00 ± 0.04 1.17 ± 0.07 
Serum free fatty acid (mEq/L) 0.77 ± 0.06 0.75 ± 0.07 0.79 ± 0.05 0.85 ± 0.06 
Serum total cholesterol (mmol/L) 1.71 ± 0.16 1.37 ± 0.03 1.09 ± 0.15b 0.87 ± 0.07 
Serum HDL-cholesterol (mmol/L) 0.59 ± 0.02 0.54 ± 0.03 0.55 ± 0.08 0.45 ± 0.07 
 
Data are the mean ± standard error (n = 5–8).  
a P < 0.05 versus untreated rats fed the MCD diet.  
bP < 0.05 versus LETO rats fed the MCD diet. 
OLETF, Otsuka Long-Evans Tokushima Fatty; LETO, Long-Evans Tokushima Otsuka; HDL-cholesterol, high density 
lipoprotein cholesterol 
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